Nateglinide, a rapidly acting insulinotrophic agent with a short duration of action, has been shown to selectively increase early insulin release in a glucose-sensitive manner. These properties have been demonstrated in vitro1 and in vivo2 in animals and in patients with type 2 diabetes mellitus.3 Nateglinide is indicated as monotherapy to lower the blood glucose levels in patients with type 2 diabetes whose hyperglycemia is not adequately controlled by diet and exercise alone and who have not been treated long-term with other antidiabetic agents.4
Sevinc A. Should Diabetic Patients Treated Long-term With Sulfonylureas Be Switched to Nateglinide? Arch Intern Med. 2003;163(14):1741. doi:10.1001/archinte.163.14.1741
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: